Biochemistry, Genetics and Molecular Biology
Myeloid
84%
Imatinib
59%
Kinase
58%
Phosphotransferase
57%
Receptor Tyrosine Kinase
38%
Tyrosine Phosphorylation
36%
Tyrosine
32%
Tyrosine Kinase
29%
Tyrosine Kinase Inhibitor
22%
Signal Transduction
20%
Eicosanoid Receptor
19%
Mesylate
17%
Cytogenetics
15%
Proteogenomics
14%
Platelet
13%
interferon
12%
Wild Type
12%
T Cell
11%
Philadelphia Chromosome
11%
Interferon
10%
Oncogene
9%
SH2 Domain
9%
Dasatinib
9%
Proteomics
8%
Phosphoprotein
8%
Drug Resistance
8%
Proto Oncogene
8%
Thrombopoietin
8%
Fusion Protein
8%
Ponatinib
7%
B Cell
7%
Point Mutation
7%
Mouse
7%
Carcinogenesis
6%
Phosphoinositide 3-Kinase
6%
Growth Factor
6%
Phosphoproteomics
6%
SH3 Domain
6%
Small Molecule
6%
STAT5
5%
T Cell Receptor
5%
Drug Response
5%
Stem Cell Transplantation
5%
Interleukin 3
5%
Cytokine
5%
Polyomavirus
5%
Keyphrases
Chronic Myeloid Leukemia
71%
BCR-ABL
42%
Imatinib
40%
Tyrosine Phosphorylation
25%
STI571
25%
Acute Myeloid Leukemia
22%
Imatinib Mesylate
17%
Tyrosine Kinase Inhibitor
16%
Tyrosine Kinase
13%
Abl Tyrosine Kinase
12%
CrkL
11%
BCR-ABL Inhibitors
11%
Phosphorylation
10%
Tyrosine
10%
Interferon-α (IFN-α)
9%
Abl Kinase
9%
Oncogene
9%
Leukemia Patients
9%
Proteogenomics
8%
Platelet-derived Growth Factor Receptor (PDGFR)
8%
Gleevec
8%
Leukemia
8%
Kinase Domain
7%
Kinase Activity
7%
SH3 Domain
7%
Philadelphia Chromosome
7%
Imatinib Resistance
7%
Phosphoinositide 3-kinase (PI3K)
6%
Targeted Therapy
6%
Phosphotyrosine
6%
Malignancy
6%
Cytogenetic Response
6%
Newly Diagnosed
6%
FMS-like Tyrosine Kinase 3 (FLT3)
6%
Granulocyte Colony-stimulating Factor (G-CSF)
6%
Signal Transduction
6%
Tyrosine Kinase Activity
5%
Platelets
5%
Dasatinib
5%
Kinase Domain mutations
5%
Imatinib Therapy
5%
Chronic Phase
5%
Drug Resistance
5%
BCR-ABL1
5%
Protein Tyrosine Phosphorylation
5%
Interleukin-3
5%
Hematological Response
5%
SH2 Domain
5%
Pharmacology, Toxicology and Pharmaceutical Science
Imatinib
100%
Chronic Myeloid Leukemia
90%
Acute Myeloid Leukemia
35%
Protein Tyrosine Kinase Inhibitor
28%
Protein Tyrosine Kinase
24%
Leukemia
22%
Phosphotransferase
22%
Abelson Kinase
20%
Malignant Neoplasm
18%
Disease
17%
Myeloid Leukemia
15%
Philadelphia 1 Chromosome
13%
Interferon
13%
Phosphotransferase Inhibitor
11%
Clinical Trial
10%
Blast Cell Crisis
9%
Acute Lymphoblastic Leukemia
9%
Dasatinib
8%
Ponatinib
6%
Drug Resistance
6%
Cytokine
6%
Cytarabine
5%
Nilotinib
5%
Receptor
5%
Neoplasm
5%
Fusion Protein
5%
